



TEVA PHARMACEUTICAL INDUSTRIES LTD.

Teva Pharmaceutical Industries Ltd.  
5 Bazel Street, P.O. Box 3190t  
Petah Tikva, 49131, Israel  
www.tevapharm.com



Lonza Group Ltd  
Muenchensteinerstrasse 38  
CH-4002 Basel, Switzerland  
www.lonza.com

## News Release

### Lonza and Teva Announce Receipt of Regulatory Approval

#### *-- Joint Venture Formally Established --*

**Jerusalem, Israel, and Basel, Switzerland, May 14, 2009** – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Lonza Group Ltd. (SIX: LONN) today announced that the European Commission granted antitrust approval to the joint venture between the two companies, which was originally announced on January 20, 2009.

In their joint venture Teva and Lonza will cooperate to develop, manufacture and market a number of affordable, efficacious and safe generic equivalents of a selected portfolio of biologic pharmaceuticals.

Teva and Lonza have now completed all formalities related to the establishment of the joint venture.

#### **About Teva**

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

#### **About Lonza**

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

###

For further information:

	<b>Teva</b>	<b>Lonza</b>
<b>Website:</b>	<a href="http://www.tevapharm.com">www.tevapharm.com</a>	<a href="http://www.lonza.com">www.lonza.com</a>
<b>Contacts:</b>	<b>Elana Holzman</b> Teva Pharmaceutical Industries Ltd. Tel. 972 (3) 926-7554 <a href="mailto:elana.holzman@teva.co.il">elana.holzman@teva.co.il</a>	<b>Media Relations</b> Dominik Werner Tel +41 61 316 8798 <a href="mailto:dominik.werner@lonza.com">dominik.werner@lonza.com</a>
	<b>Kevin Mannix</b> Teva North America Tel. (215) 591-8912 <a href="mailto:kevin.mannix@tevausa.com">kevin.mannix@tevausa.com</a>	<b>Investor Relations</b> Alexandre Pasini Tel +41 61 316 8835 <a href="mailto:alexandre.pasini@lonza.com">alexandre.pasini@lonza.com</a>

**Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:**

*Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel® and Protonix®, the current economic conditions, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the effects of competition on our innovative products, especially Copaxone® sales, dependence on the effectiveness of our patents and other protections for innovative products, especially Copaxone®, the impact of consolidation of our distributors and customers, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the uncertainty surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, the regulatory environment and changes in the health policies and structures of various countries, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, our ability to successfully identify, consummate and integrate acquisitions, including the integration of Barr Pharmaceuticals, Inc., the potential exposure to product liability claims to the extent not covered by insurance, our exposure to fluctuations in currency, exchange and interest rates, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, our ability to enter into patent litigation settlements and the intensified scrutiny by the U.S. government, the termination or expiration of governmental programs and tax benefits, impairment of intangible assets and goodwill, environmental risks, and other factors that are discussed in our Annual Report on Form 20-F and in our other filings with the U.S. Securities and Exchange Commission ("SEC").*